FDA Launches Real-Time Clinical Trial Monitoring Initiative Using AI

The FDA announced on April 28, 2026, a real-time clinical trial monitoring initiative that uses AI-powered cloud-based systems to allow regulators to see trial endpoints as they occur rather than waiting for final results. The program follows a successful proof-of-concept trial by AstraZeneca with MD Anderson Cancer Center and University of Pennsylvania, with Amgen now setting up its own real-time trial and a broader pilot launching summer 2026. FDA Commissioner Marty Makary, a former Johns Hopkins surgical oncologist, frames the initiative as addressing inefficiencies in drug development where 45% of the typical 10-year timeline involves no active trials. The real-time monitoring program is part of broader FDA modernization efforts that include replacing animal testing with computational modeling and a National Priority Voucher program that has approved six drugs with 1-2 month reviews instead of the typical 10-12 months.

Real-Time Clinical Trial Monitoring System and Technology

• ▪The FDA established a technical framework powered by artificial intelligence and modern data science to securely stream and validate key safety and efficacy signals as clinical trials progress
• ▪AstraZeneca conducted a proof-of-concept clinical trial that reports endpoints and data signals to the FDA in real time
• ▪FDA regulators will be able to see clinical trial endpoints in the cloud as they occur for the first time
• ▪The University of Texas MD Anderson Cancer Center participated in the AstraZeneca proof-of-concept real-time clinical trial
• ▪The FDA will launch a broader real-time clinical trials pilot program in summer 2026
• ▪The FDA announced a real-time clinical trials initiative on Tuesday, April 28, 2026

Reduction of Drug Development Timeline and Dead Time

• ▪A new drug takes 10 years on average to come to market
• ▪45% of the time from a Phase 1 trial until final submission is spent without any ongoing clinical trial in progress

Broader FDA Modernization Initiatives and Approved Treatments

• ▪Six drugs have been approved through the FDA National Priority Voucher pilot program
• ▪The FDA launched a National Priority Voucher pilot program to get review decisions out in one to two months instead of the typical 10 months to a year
• ▪Marty Makary is commissioner of the Food and Drug Administration
• ▪Marty Makary worked as a surgical oncologist at Johns Hopkins

Perspective of Marty Makary

• ▪Marty Makary positions the real-time clinical trials program alongside other FDA reforms including replacing animal testing with computational modeling
• ▪Marty Makary highlights zongertinib and otarmeni as examples of life-changing drugs that benefited from FDA's accelerated National Priority Voucher program
• ▪Marty Makary views the FDA real-time clinical trials initiative as addressing inefficiencies where nearly half of drug development time involves no active trials

Perspective of Pharmaceutical companies (AstraZeneca and Amgen)

• ▪Pharmaceutical companies participating in FDA real-time clinical trials can potentially reduce the 10-year average timeline for bringing new drugs to market

Perspective of Academic medical centers

• ▪The University of Texas MD Anderson Cancer Center and University of Pennsylvania are testing whether real-time data streaming maintains data integrity and patient safety in actual clinical environments